NCT04256473View on ClinicalTrials.gov

Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 10, 2019

Primary Completion Date

March 26, 2022

Study Completion Date

May 26, 2022

Conditions
Ischemic Stroke
Interventions
DRUG

mutant pro-urokinase

Intravenous administration

DRUG

Alteplase

Intravenous administration

Trial Locations (1)

3000 CA

DUMAS trial office, Rotterdam

Sponsors
All Listed Sponsors
collaborator

DUMAS is sponsored by an unrestricted grant from Thrombolytic Science International, paid to the institution.

UNKNOWN

lead

Erasmus Medical Center

OTHER